GCLC and acute myeloid leukemia: CRISPR/Cas9 has been used to knock out genes like the Glutamate–cysteine ligase catalytic subunit, GCLC (a key enzyme in glutathione synthesis), in Acute myeloid leukemia (AML) and solid tumors [222] to increase their sensitivity to oxidative damage, making them more susceptible to chemotherapy and radiotherapy.